Thông tin thuốc gốc
Chỉ định và Liều dùng
Advanced renal cell carcinoma
Adult: Initially, 5 mg bid (given approx 12 hrly), may be increased further to 7 mg bid, then 10 mg bid, if the initial dose is tolerated (patients w/ no AR above grade 2, w/ normal BP, and are not receiving antihypertensive therapy) for at least 2 consecutive wk. If dosage reduction is needed due to AR, 5 mg bid dose may be reduced to 3 mg bid and further to 2 mg bid.
Nhóm bệnh nhân đặc biệt
Patients taking strong CYP3A4/5 inhibitors: Reduce to approx 50% of the usual initial dose (e.g. 5 mg bid reduced to 2 mg bid), w/ further adjustments according to response.
Suy gan
Moderate (Child-Pugh Class B): Reduce to approx 50% of the usual initial dose (e.g. 5 mg bid reduced to 2 mg bid), w/ further adjustments according to response. Severe (Child-Pugh Class C): Contraindicated.
Cách dùng
May be taken with or without food.
Chống chỉ định
Recent active GI bleeding, untreated brain metastases. Severe hepatic impairment (Child-Pugh Class C). Lactation.
Thận trọng
Patient w/ HTN, cardiac disease, history of or risk for thrombosis. Patients taking strong CYP3A4 inhibitors. Withhold treatment at least 24 hr prior to scheduled surgery. Moderate hepatic impairment (Child-Pugh Class B). Pregnancy.
Tác dụng không mong muốn
Significant: HTN, posterior reversible leukoencephalopathy syndrome, proteinuria, thyroid dysfunction, increased Hb or haematocrit, impaired wound healing.
Nervous: Headache, fatigue, asthenia.
GI: GI disturbance, decreased appetite, nausea, vomiting, oral mucositis, taste disturbance, vocal changes, dysphonia, abdominal pain, dyspepsia, diarrhoea, constipation.
Hepatic: Increased hepatic enzymes and bilirubin.
Endocrine: Wt loss.
Musculoskeletal: Arthralgia, myalgia.
Dermatologic: Palmar-plantar erythrodysaesthesia, rash, dry skin, itch, erythema, alopecia.
Others: Electrolyte disturbance.
Potentially Fatal: Cardiac failure, arterial thrombotic events (e.g. MI, TIA, CVA, retinal artery exclusion), venous thrombotic events (e.g. DVT, pulmonary embolism, retinal vein occlusion or thrombosis), hypertensive crisis, haemorrhagic events (e.g. GI or cerebral haemorrhage, haemoptysis, haematuria, melaena), GI perforation and fistula formation.
Thông tin tư vấn bệnh nhân
This drug may cause dizziness and fatigue, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor BP, Hb or haematocrit, LFT, thyroid function, and urinalysis (for proteinuria) prior to and during treatment.
Quá liều
Symptoms: Dizziness, HTN, seizures, haemoptysis. Management: Supportive treatment.
Tương tác
Plasma concentration is increased by strong CYP3A4/5 inhibitors (e.g. ketoconazole, ritonavir, clarithromycin) and decreased by strong CYP3A4/5 inducers (e.g. rifampicin, phenytoin, carbamazepine). May enhance adverse effects (e.g. osteonecrosis of the jaw) of bisphosphonate derivatives.
Tương tác với thức ăn
Increased plasma concentrations w/ grapefruit or grapefruit juice. Reduced plasma concentrations w/ St John’s wort.
Tác dụng
Description: Axitinib, a selective 2nd generation tyrosine kinase inhibitor, blocks angiogenesis, tumour growth, and cancer progression by inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3).
Absorption: Rapidly absorbed from the GI tract. Bioavailability: Approx 58%. Time to peak plasma concentration: 2.5-4 hr.
Distribution: Volume of distribution: 160 L. Plasma protein binding: >99%, mainly to albumin and α1-acid glycoprotein.
Metabolism: Metabolised in the liver mainly by CYP3A4/5, and to a lesser extent by CYP1A2, CYP2C19, and UGT1A1.
Excretion: Via faeces (approx 41%, 12% as unchanged drug) and urine (approx 23%, as metabolites). Elimination half-life: 2.5-6.1 hr.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Axitinib, CID=6450551, (accessed on Jan. 21, 2020)

Bảo quản
Store between 20-25°C.
This is a cytotoxic drug. Use appropriate personal protective equipment (e.g. gloves) for receiving, handling, admin, and disposal. Any unused portions should be disposed of in accordance w/ local requirements.
Phân loại MIMS
Liệu pháp nhắm trúng đích
Phân loại ATC
L01EK01 - axitinib ; Belongs to the class of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors. Used in the treatment of cancer.
Tài liệu tham khảo
Anon. Axitinib. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 03/05/2017 .

Buckingham R (ed). Axitinib. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 03/05/2017 .

Inlyta Tablet, Film Coated (Pfizer Laboratories Div, Pfizer Inc). DailyMed. Source: U.S. National Library of Medicine. Accessed 03/05/2017 .

Joint Formulary Committee. Axitinib. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 03/05/2017 .

McEvoy GK, Snow EK, Miller J et al (eds). Axitinib. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 03/05/2017 .

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Axitinib từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in